Skip to main content
Top
Published in: International Journal of Hematology 4/2009

01-05-2009 | Letter to the Editor

Use of tranexamic acid for disseminated intravascular coagulation with excessive fibrinolysis associated with aortic dissection in a patient with chronic renal failure

Authors: Shun-ichi Kimura, Jun Odawara, Takatoshi Aoki, Masayuki Yamakura, Masami Takeuchi, Yoshihiko Watanabe, Kosei Matsue

Published in: International Journal of Hematology | Issue 4/2009

Login to get access

Excerpt

Disseminated intravascular coagulation (DIC) is characterized by systemic activation of coagulation, which leads to the intravascular formation of fibrin and depletion of platelets and coagulation factors [1]. Secondary fibrinolysis is seen in patients with DIC, but the degree to which the fibrinolytic system activated varies according to underlying diseases. Aortic aneurysm and aortic dissection are rare but well-recognized causes of DIC [24]; however, the degree of activation of fibrinolytic system seems to differ and the optimal medical treatment strategy, especially in inoperable cases, has not been established yet. Furthermore, there have been few reports which referred to the DIC treatment in patients with renal failure and optimal treatment such as the choice and the dosage of drugs in these conditions is unclear. We report here a case of chronic DIC accompanied by excessive fibrinolytic activity with marked bleeding tendency due to inoperable aortic dissection in a patient with chronic kidney disease under hemodialysis, which was successfully controlled by combined use of tranexamic acid (TA, an antifibrinolytic agent) and anticoagulant. …
Literature
5.
go back to reference Asakura H, Jokaji H, Saito M, Uotani C, Kumabashiri I, Morishita E, et al. Study of the balance between coagulation and fibrinolysis in disseminated intravascular coagulation using molecular markers. Blood Coagul Fibrinolysis. 1994;5:829–32. doi:10.1097/00001721-199410000-00022.CrossRefPubMed Asakura H, Jokaji H, Saito M, Uotani C, Kumabashiri I, Morishita E, et al. Study of the balance between coagulation and fibrinolysis in disseminated intravascular coagulation using molecular markers. Blood Coagul Fibrinolysis. 1994;5:829–32. doi:10.​1097/​00001721-199410000-00022.CrossRefPubMed
6.
go back to reference Kario K, Matsuo T, Kodama K, Matsuo M, Yamamoto K, Kobayashi H. Imbalance between thrombin and plasmin activity in disseminated intravascular coagulation. Assessment by the thrombin-antithrombin-III complex/plasmin-alpha-2-antiplasmin complex ratio. Haemostasis. 1992;22:179–86.PubMed Kario K, Matsuo T, Kodama K, Matsuo M, Yamamoto K, Kobayashi H. Imbalance between thrombin and plasmin activity in disseminated intravascular coagulation. Assessment by the thrombin-antithrombin-III complex/plasmin-alpha-2-antiplasmin complex ratio. Haemostasis. 1992;22:179–86.PubMed
8.
go back to reference Okajima K, Kohno I, Soe G, Okabe H, Takatsuki K, Binder BR. Direct evidence for systemic fibrinogenolysis in patients with acquired alpha 2-plasmin inhibitor deficiency. Am J Hematol. 1994;45:16–24. doi:10.1002/ajh.2830450104.CrossRefPubMed Okajima K, Kohno I, Soe G, Okabe H, Takatsuki K, Binder BR. Direct evidence for systemic fibrinogenolysis in patients with acquired alpha 2-plasmin inhibitor deficiency. Am J Hematol. 1994;45:16–24. doi:10.​1002/​ajh.​2830450104.CrossRefPubMed
9.
go back to reference Nilsson IM. Clinical pharmacology of aminocaproic and tranexamic acids. J Clin Pathol Suppl (R Coll Pathol). 1980;14:41–7.CrossRef Nilsson IM. Clinical pharmacology of aminocaproic and tranexamic acids. J Clin Pathol Suppl (R Coll Pathol). 1980;14:41–7.CrossRef
10.
go back to reference Brandrook ID, Magnani HN, Moelker HC, Morrison PJ, Robinson J, Rogers HJ, et al. ORG 10172: a low molecular weight heparinoid anticoagulant with a long half-life in man. Br J Clin Pharmacol. 1987;23:667–75.CrossRef Brandrook ID, Magnani HN, Moelker HC, Morrison PJ, Robinson J, Rogers HJ, et al. ORG 10172: a low molecular weight heparinoid anticoagulant with a long half-life in man. Br J Clin Pharmacol. 1987;23:667–75.CrossRef
11.
go back to reference Ontachi Y, Asakura H, Arahata M, Kadohira Y, Maekawa M, Hayashi T, et al. Effect of combined therapy of danaparoid sodium and tranexamic acid on chronic disseminated intravascular coagulation associated with abdominal aortic aneurysm. Circ J. 2005;69:1150–3. doi:10.1253/circj.69.1150.CrossRefPubMed Ontachi Y, Asakura H, Arahata M, Kadohira Y, Maekawa M, Hayashi T, et al. Effect of combined therapy of danaparoid sodium and tranexamic acid on chronic disseminated intravascular coagulation associated with abdominal aortic aneurysm. Circ J. 2005;69:1150–3. doi:10.​1253/​circj.​69.​1150.CrossRefPubMed
12.
go back to reference Ontachi Y, Asakura H, Omote M, Yoshida T, Matsui O, Nakao S. Kasabach–Merritt syndrome associated with giant liver hemangioma: the effect of combined therapy with danaparoid sodium and tranexamic acid. Haematologica. 2005;90(Suppl):ECR29.PubMed Ontachi Y, Asakura H, Omote M, Yoshida T, Matsui O, Nakao S. Kasabach–Merritt syndrome associated with giant liver hemangioma: the effect of combined therapy with danaparoid sodium and tranexamic acid. Haematologica. 2005;90(Suppl):ECR29.PubMed
15.
go back to reference Rodeghiero F, Avvisati G, Castaman G, Barbui T, Mandelli F. Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients. Blood. 1990;75:2112–7.PubMed Rodeghiero F, Avvisati G, Castaman G, Barbui T, Mandelli F. Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients. Blood. 1990;75:2112–7.PubMed
16.
go back to reference Sanz MA, Martin G, Gonzalez M, Leon A, Rayon C, Rivas C, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monotherapy: a multicenter study by the PATHEMA group. Blood. 2004;103:1237–43. doi:10.1182/blood-2003-07-2462.CrossRefPubMed Sanz MA, Martin G, Gonzalez M, Leon A, Rayon C, Rivas C, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monotherapy: a multicenter study by the PATHEMA group. Blood. 2004;103:1237–43. doi:10.​1182/​blood-2003-07-2462.CrossRefPubMed
17.
go back to reference Hashimoto S, Koike T, Tatewaki W, Seki Y, Sato N, Azegami T, et al. Fatal thromboembolism in acute promyelocytic leukemia during all-trans retinoic acid therapy combined with antifibrinolytic therapy for prophylaxis of hemorrhage. Leukemia. 1994;8:1113–5.PubMed Hashimoto S, Koike T, Tatewaki W, Seki Y, Sato N, Azegami T, et al. Fatal thromboembolism in acute promyelocytic leukemia during all-trans retinoic acid therapy combined with antifibrinolytic therapy for prophylaxis of hemorrhage. Leukemia. 1994;8:1113–5.PubMed
18.
go back to reference Koseki M, Asada N, Uryu H, Takeuchi M, Asakura H, Matsue K. Successful combined use of tranexamic acid and unfractionated heparin for life-threatening bleeding associated with intravascular coagulation in a patient with chronic myelogenous leukemia in blast crisis. Int J Hematol. 2007;86:403–6. doi:10.1007/BF02983996.CrossRefPubMed Koseki M, Asada N, Uryu H, Takeuchi M, Asakura H, Matsue K. Successful combined use of tranexamic acid and unfractionated heparin for life-threatening bleeding associated with intravascular coagulation in a patient with chronic myelogenous leukemia in blast crisis. Int J Hematol. 2007;86:403–6. doi:10.​1007/​BF02983996.CrossRefPubMed
Metadata
Title
Use of tranexamic acid for disseminated intravascular coagulation with excessive fibrinolysis associated with aortic dissection in a patient with chronic renal failure
Authors
Shun-ichi Kimura
Jun Odawara
Takatoshi Aoki
Masayuki Yamakura
Masami Takeuchi
Yoshihiko Watanabe
Kosei Matsue
Publication date
01-05-2009
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 4/2009
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-009-0309-2

Other articles of this Issue 4/2009

International Journal of Hematology 4/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine